350 related articles for article (PubMed ID: 29632047)
1. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
[TBL] [Abstract][Full Text] [Related]
2. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
3. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
4. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
Gillis JL; Selth LA; Centenera MM; Townley SL; Sun S; Plymate SR; Tilley WD; Butler LM
Oncotarget; 2013 May; 4(5):691-704. PubMed ID: 23674566
[TBL] [Abstract][Full Text] [Related]
5. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.
Voruganti S; Lacroix JC; Rogers CN; Rogers J; Matts RL; Hartson SD
J Proteome Res; 2013 Aug; 12(8):3697-706. PubMed ID: 23763277
[TBL] [Abstract][Full Text] [Related]
6. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
7. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.
Armstrong HK; Gillis JL; Johnson IRD; Nassar ZD; Moldovan M; Levrier C; Sadowski MC; Chin MY; Tomlinson Guns ES; Tarulli G; Lynn DJ; Brooks DA; Selth LA; Centenera MM; Butler LM
Sci Rep; 2018 Feb; 8(1):2090. PubMed ID: 29391407
[TBL] [Abstract][Full Text] [Related]
9. Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
Nassar ZD; Mah CY; Centenera MM; Irani S; Sadowski MC; Scott JS; Nguyen EV; Nagarajan SR; Moldovan M; Lynn DJ; Daly RJ; Hoy AJ; Butler LM
Mol Cancer Res; 2020 Oct; 18(10):1500-1511. PubMed ID: 32669400
[TBL] [Abstract][Full Text] [Related]
10. Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
Marrugal Á; Ferrer I; Pastor MD; Ojeda L; Quintanal-Villalonga Á; Carnero A; Molina-Pinelo S; Paz-Ares L
Cells; 2019 Jul; 8(8):. PubMed ID: 31370342
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
Li QQ; Hao JJ; Zhang Z; Krane LS; Hammerich KH; Sanford T; Trepel JB; Neckers L; Agarwal PK
Sci Rep; 2017 Mar; 7(1):201. PubMed ID: 28298630
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
[TBL] [Abstract][Full Text] [Related]
16. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition.
Oikonomopoulou K; Soosaipillai A; Diamandis EP
Clin Biochem; 2009 Nov; 42(16-17):1705-12. PubMed ID: 19632215
[TBL] [Abstract][Full Text] [Related]
18. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
19. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]